4-Hydroxymandelic Acid for HPDL-Related CoQ10 Biosynthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for new therapeutics for pancreatic cancer and diseases associated with CoQ10 deficiency and HPDL gene variations, such as cerebral palsy, as well as improved methods for isotopic labeling of gases in cells.
Innovation Solution
Administering 4-hydroxymandelic acid (4-HMA) or its metabolites, along with activators like vitamin C, to treat HPDL-related diseases and increase CoQ10 biosynthesis by targeting mutations in the HPDL gene and related genes, and using specific inhibitors to modulate HPDL expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If CoQ10 supplementation is used to treat CoQ10 deficiency, then CoQ10 levels may increase, but the pharmacokinetics are not well understood and absorption efficiency is uncertain
Solution Approach 1:
The patent uses 4-hydroxymandelic acid (4-HMA) as an intermediary substance that can be converted to CoQ10 in the body. By administering 4-HMA instead of direct CoQ10 supplementation, the invention bypasses the unknown pharmacokinetic barriers of CoQ10 absorption while still achieving the therapeutic goal of increasing CoQ10 levels through endogenous conversion pathways.
2Reliability
If HPDL gene mutations are present, then CoQ10 biosynthesis is impaired, but direct gene therapy is complex and not yet clinically feasible
Solution Approach 1:
Instead of attempting to fix the defective HPDL gene directly through complex gene therapy approaches, the invention inverts the strategy by bypassing the defective enzyme pathway entirely. It uses alternative substrates (4-HMA, 4-HB, mevalonate) that can feed into the CoQ10 biosynthesis pathway downstream of the HPDL enzyme, thereby circumventing the genetic defect through metabolic workarounds.
3Reliability
If pancreatic cancer is treated with conventional therapies, then some tumors respond, but pancreatic ductal adenocarcinoma has only 9% 5-year survival rate indicating treatment resistance
Solution Approach 1:
The patent targets the metabolic parameters of pancreatic cancer cells by disrupting their altered CoQ10 biosynthesis pathway. Since pancreatic cancer cells exhibit hypoxia and altered metabolism, the invention uses compounds (4-HMA, 4-HB, mevalonate) that can modulate the metabolic state of tumor cells, potentially reversing the adaptive resistance that conventional therapies cannot overcome.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The methods effectively treat HPDL-related diseases and increase CoQ10 biosynthesis, addressing the unmet needs for therapeutic interventions and providing targeted treatment strategies.
Implementation Method 1
4-hydroxyphenylpyruvate dioxygenase-like (HPDL) is an enzyme involved in CoQ10 biosynthesis
Implementation Method 2
activators like vitamin C, to treat HPDL-related diseases and increase CoQ10 biosynthesis by targeting mutations in the HPDL gene
Data Source
AI summary
Various methods and compositions of treating 4-hydroxyphenylpyruvate dioxygenase-like (HPDL)-related diseases or disorders are presented herein. Also presented herein are methods of increasing CoQ10 biosynthesis, and methods of determining whether a subject will benefit from a CoQ10 or CoQ10 alternative treatment. Also presented herein are pharmaceutical compositions and dosage forms comprising 4-hydroxymandelic acid (4-HMA), and/or its metabolites. Further presented herein are compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase-like (HPDL). Further presented herein are methods of identifying and/or assessing modulators of HPDL. Yet further presented herein are example methods and systems for isotopic labelling in cells by metabolizing cells in the presence of gaseous isotopic tracer.